Granulocytapheresis in the treatment of patients with active ulcerative colitis

References

• Saverymuttu SH, Chadwick VS, Hodgson HJ. Granulocyte migration in ulcerative colitis. Eur. J. Clin. Invest.15(2), 60–63 (1985).
   PubMedGoogle Scholar
• Saverymuttu SH, Peters AM, Crofton ME et al. 111Indium autologous granulocytes in the detection of inflammatory bowel disease. Gut26(9), 955–960 (1985).
   PubMed Web of Science ®Google Scholar
• Rugtveit J, Brandtzaeg P, Halstensen TS, Fausa O, Scott H. Increased macrophage subset in inflammatory bowel disease: apparent recruitment from peripheral blood monocytes. Gut35(5), 669–674 (1994).
   PubMed Web of Science ®Google Scholar
• Seegert D, Rosenstiel P, Pfahler H, Pfefferkorn P, Nikolaus S, Schreiber S. Increased expression of IL-16 in inflammatory bowel disease. Gut48(3), 326–332 (2001).
   PubMedGoogle Scholar
• Nielsen OH, Rudiger N, Gaustadnes M, Horn T. Intestinal interleukin-8 concentration and gene expression in inflammatory bowel disease. Scand. J. Gastroenterol.32(10), 1028–1034 (1997).
   PubMed Web of Science ®Google Scholar
• Nikolaus S, Bauditz J, Gionchetti P, Witt C, Lochs H, Schreiber S. Increased secretion of pro-inflammatory cytokines by circulating polymorphonuclear neutrophils and regulation by interleukin-10 during intestinal inflammation. Gut42(4), 470–476 (1998).
   PubMed Web of Science ®Google Scholar
• Janczewska I, Stal P, Sandstedt B. Transformation of microscopic colitis to inflammatory bowel disease. Lakartidningen.104(20,21), 1597–1598 (2007).
   PubMedGoogle Scholar
• Nusrat A, Turner JR, Madara JL. Molecular physiology and pathophysiology of tight junctions. IV. Regulation of tight junctions by extracellular stimuli: nutrients, cytokines, and immune cells. Am. J. Physiol. Gastrointest. Liver Physiol.279(5), G851–G857 (2000).
   PubMed Web of Science ®Google Scholar
• Tibble JA, Sigthorsson G, Foster R, Forgacs I, Bjarnason I. Use of surrogate markers of inflammation and Rome criteria to distinguish organic from nonorganic intestinal disease. Gastroenterology124(4), 1164–1165 (2003).
   PubMedGoogle Scholar
• Hanai H, Takeuchi K, Iida T et al. Relationship between fecal calprotectin, intestinal inflammation, and peripheral blood neutrophils in patients with active ulcerative colitis. Dig. Dis. Sci.49(9), 1438–1443 (2004).
   PubMed Web of Science ®Google Scholar
• Berni CR, Terrin G, Rapacciuolo L et al. Faecal calprotectin as reliable non-invasive marker to assess the severity of mucosal inflammation in children with inflammatory bowel disease. Dig. Liver Dis.40(7), 547–553 (2008).
   PubMedGoogle Scholar
• Truelove SC, Witts LJ. Cortisone in ulcerative colitis. Final report on therapeutic trial. Br. Med. J.2, 1041–1048 (1955).
   PubMed Web of Science ®Google Scholar
• Lichtenstein GR, Abreu MT, Cohen R, Tremaine W. American Gastroenterological Association Institute medical position statement on corticosteroids, immunomodulators and infliximab in inflammatory bowel disease. Gastroenterology130, 935–939 (2006).
   PubMed Web of Science ®Google Scholar
• Porro GB, Cassinotti A, Ferrara E, Maconi G, Ardizzone S. Review article: the management of steroid dependency in ulcerative colitis. Aliment. Pharmacol. Ther.26(6), 779–794 (2007).
   PubMedGoogle Scholar
• Bean RH. The treatment of chronic ulcerative colitis with 6-mercaptopurine. Med. J. Aust.49, 592–593 (1962).
   PubMed Web of Science ®Google Scholar
• Bowen GE, Irons GV, Rhodes JB. Early experiences with azathioprine in ulcerative colitis. A note of caution. JAMA195, 460–464 (1966).
   PubMed Web of Science ®Google Scholar
• Lichtiger S, Present DH, Kornbluth A. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N. Engl. J. Med.330, 1841–1845 (1994).
   PubMed Web of Science ®Google Scholar
• Su C, Lichtenstein GR. Treatment of inflammatory bowel disease with azathioprine and 6-mercaptopurine. Gastroenterol. Clin. North Am.33(2), 209–234, viii (2004).
   PubMedGoogle Scholar
• Gourlay T, Olivencia-Yurvati AH, Gunaydin S. STS blood conservation guidelines: the role of leukocyte filtration. Ann. Thorac. Surg.85(3), 1138–1139 (2008).
   PubMedGoogle Scholar
• Bosch T. Therapeutic apheresis-state of the art in the year 2005. Ther. Apher. Dial.9(6), 459–468 (2005).
   PubMedGoogle Scholar
• Kennedy MS, Domen RE. Therapeutic apheresis. Applications and future directions. Vox Sang.45, 261–277 (1983).
   PubMedGoogle Scholar
• Abreu MT, Plevy S, Sands BE, Weinstein R. Selective leukocyte apheresis for the treatment of inflammatory bowel disease. J. Clin. Gastroenterol.41(10), 874–888 (2007).
   PubMed Web of Science ®Google Scholar
• Sawada K, Muto T, Shimoyama T et al. Multicenter randomized controlled trial for the treatment of ulcerative colitis with a leukocytapheresis column. Curr. Pharm. Des.9(4), 307–321 (2003).
   PubMed Web of Science ®Google Scholar
• Nishioka C, Aoyama N, Maekawa S et al. Leukocytapheresis therapy for steroid-naive patients with active ulcerative colitis: its clinical efficacy and adverse effects compared with those of conventional steroid therapy. J. Gastroenterol. Hepatol.20(10), 1567–1571 (2005).
   PubMedGoogle Scholar
• Fukunaga K, Sawada K, Chikano S et al. [Leukocytapheresis for ulcerative colitis]. Nippon Rinsho.57(11), 2496–2502 (1999).
   PubMedGoogle Scholar
• Sawada K, Kusugami K, Suzuki Y et al. Leukocytapheresis in ulcerative colitis: results of a multicenter double-blind prospective case-control study with sham apheresis as placebo treatment. Am. J. Gastroenterol.100(6), 1362–1369 (2005).
   PubMed Web of Science ®Google Scholar
• Sawada K, Ohnishi K, Fukunaga K et al. [Mechanism of leukocytapheresis effect in the treatment of ulcerative colitis]. Nihon Rinsho Meneki Gakkai Kaishi22(6), 469–474 (1999).
   PubMedGoogle Scholar
• Sawada K, Ohnishi K, Kosaka T et al. [Leukocytapheresis for ulcerative colitis]. Nippon Geka Gakkai Zasshi98(4), 438–442 (1997).
   PubMedGoogle Scholar
• Emmrich J, Petermann S, Nowak D et al. Leukocytapheresis (LCAP) in the management of chronic active ulcerative colitis–results of a randomized pilot trial. Dig. Dis. Sci.52(9), 2044–2053 (2007).
   PubMedGoogle Scholar
• Ramlow W, Emmrich J, Ahrenholz P et al.In vitro and in vivo evaluation of Adacolumn cytapheresis in healthy subjects. J. Clin. Apher.20(2), 72–80 (2005).
   PubMedGoogle Scholar
• Saniabadi AR, Hanai H, Takeuchi K et al. Adacolumn, an adsorptive carrier based granulocyte and monocyte apheresis device for the treatment of inflammatory and refractory diseases associated with leukocytes. Ther. Apher. Dial.7(1), 48–59 (2003).
   PubMed Web of Science ®Google Scholar
• Saniabadi AR, Hanai H, Fukunaga K et al. Therapeutic leukocytapheresis for inflammatory bowel disease. Transfus. Apher. Sci.37(2), 191–200 (2007).
   PubMed Web of Science ®Google Scholar
• Yamamoto T, Umegae S, Kitagawa T et al. Granulocyte and monocyte adsorptive apheresis in the treatment of active distal ulcerative colitis: a prospective, pilot study. Aliment. Pharmacol. Ther.20(7), 783–792 (2004).
   PubMed Web of Science ®Google Scholar
• Kanke K, Nakano M, Hiraishi H, Terano A. Clinical evaluation of granulocyte/monocyte apheresis therapy for active ulcerative colitis. Dig. Liver Dis.36(12), 811–817 (2004).
   PubMedGoogle Scholar
• Domènech E, Hinojosa J, Esteve-Comas M et al.; Spanish Group for the Study of Crohn’s Disease and Ulcerative Colitis (GETECCU). Granulocyteaphaeresis in steroid-dependent inflammatory bowel disease: a prospective, open, pilot study. Aliment. Pharmacol. Ther.20(11,12), 1347–1352 (2004).
   PubMed Web of Science ®Google Scholar
• Sands BE, Sandborn WJ, Wolf DC et al. Pilot feasibility studies of leukocytapheresis with the Adacolumn Apheresis System in patients with active ulcerative colitis or Crohn disease. J. Clin. Gastroenterol.40(6), 482–489 (2006).
   PubMed Web of Science ®Google Scholar
• Kashiwagi N, Sugimura K, Koiwai H et al. Immunomodulatory effects of granulocyte and monocyte adsorption apheresis as a treatment for patients with ulcerative colitis. Dig. Dis. Sci.47(6), 1334–1341 (2002).
   PubMed Web of Science ®Google Scholar
• Saniabadi AR, Hanai H, Suzuki Y et al. Adacolumn for selective leukocytapheresis as a non-pharmacological treatment for patients with disorders of the immune system: an adjunct or an alternative to drug therapy? J. Clin. Apher.20(3), 171–184 (2005).
   PubMed Web of Science ®Google Scholar
• Hiraishi K, Takeda Y, Shiobara N et al. Studies on the mechanisms of leukocyte adhesion to cellulose acetate beads: an in vitro model to assess the efficacy of cellulose acetate carrier-based granulocyte and monocyte adsorptive apheresis. Ther. Apher. Dial.7(3), 334–340 (2003).
   PubMed Web of Science ®Google Scholar
• Soerensen H, Schneidewind-Mueller JM, Lange D et al. Pilot clinical study of Adacolumn cytapheresis in patients with systemic lupus erythematosus. Rheumatol. Int.26(5), 409–415 (2006).
   PubMedGoogle Scholar
• Yamaji K, Tsuda H, Hashimoto H. Current topics on cytapheresis technologies. Ther. Apher.5(4), 287–292 (2001).
   PubMedGoogle Scholar
• Ohara M, Saniabadi AR, Kokuma S et al. Granulocytapheresis in the treatment of patients with rheumatoid arthritis. Artif. Organs21(9), 989–994 (1997).
   PubMed Web of Science ®Google Scholar
• Yonekawa M, Kawamura A, Komai T, Agishi T, Adachi M. Extracorporeal granulocytapheresis for cancer and rheumatoid arthritis. Transfus. Sci.17(3), 463–472 (1996).
   PubMedGoogle Scholar
• Sawada K, Ohnishi K, Kosaka T et al. Leukocytapheresis therapy with leukocyte removal filter for inflammatory bowel disease. J. Gastroenterol.30(Suppl. 8), 124–127 (1995).
   PubMedGoogle Scholar
• Sawada K, Ohnishi K, Fukui S et al. Leukocytapheresis therapy, performed with leukocyte removal filter, for inflammatory bowel disease. J. Gastroenterol.30(3), 322–329 (1995).
   PubMed Web of Science ®Google Scholar
• Kawamura A, Saitoh M, Yonekawa M et al. New technique of leukocytapheresis by the use of nonwoven polyester fiber filter for inflammatory bowel disease. Ther. Apher.3(4), 334–337 (1999).
   PubMedGoogle Scholar
• Shimoyama T, Sawada K, Hiwatashi N et al. Safety and efficacy of granulocyte and monocyte adsorption apheresis in patients with active ulcerative colitis: a multicenter study. J. Clin. Apher.16(1), 1–9 (2001).
   PubMed Web of Science ®Google Scholar
• Kanke K, Nakano M, Hiraishi H, Terano A. Clinical evaluation of granulocyte/monocyte apheresis therapy for active ulcerative colitis. Dig. Liver Dis.36(12), 811–817 (2004).
   PubMedGoogle Scholar
• Suzuki Y, Yoshimura N, Saniabadi AR, Saito Y. Selective granulocyte and monocyte adsorptive apheresis as a first-line treatment for steroid naive patients with active ulcerative colitis: a prospective uncontrolled study. Dig. Dis. Sci.49(4), 565–571 (2004).
   PubMed Web of Science ®Google Scholar
• Sawada K, Kazuo K, Suzuki Y et al. Leukocytapheresis in ulcerative colitis: results of multicenter double-blind prospective case-control study with sham apheresis as placebo treatment. Am. J. Gastroenterol.100(6), 1362–1369 (2005).
   PubMed Web of Science ®Google Scholar
• Hanai H, Watanabe F, Takeuchi K et al. Leukocyte adsorptive apheresis for the treatment of active ulcerative colitis: a prospective, uncontrolled, pilot study. Clin. Gastroenterol. Hepatol.1(1), 28–35 (2003).
   PubMed Web of Science ®Google Scholar
• Hanai H, Watanabe F, Yamada M et al. Adsorptive granulocyte and monocyte apheresis versus prednisolone in patients with corticosteroid-dependent moderately severe ulcerative colitis. Digestion70(1), 36–44 (2004).
   PubMed Web of Science ®Google Scholar
• Naganuma M, Funakoshi S, Sakuraba A et al. Granulocytapheresis is useful as an alternative therapy in patients with steroid-refractory or -dependent ulcerative colitis. Inflamm. Bowel Dis.10(3), 251–257 (2004).
   PubMed Web of Science ®Google Scholar
• Kruis W, Dignass A, Steinhagen-Thiessen E et al. Open label trial of granulocyte apheresis suggests therapeutic efficay in cronically active steroid refractory ulcerative colitis. World J. Gastroenterol.11(44), 7001–7006 (2005).
   PubMed Web of Science ®Google Scholar
• Bresci G, Parisi G, Bertoni M, Mazzoni A, Scatena F, Capria A. Treatment with granulocytapheresis of active steroid-refractory inflammatory bowel diseases. Our experience with a prospective study. World J. Gastroenterol.12(14), 2201–2204 (2006).
   PubMed Web of Science ®Google Scholar
• D’Ovidio V, Aratari A, Viscido A et al. Mucosal features and granulocyte-monocyte-apheresis in steroid-dependent/refractory ulcerative colitis. Dig. Liver Dis.38, 389–394 (2006).
   PubMedGoogle Scholar
• Bresci G, Parisi G, Mazzoni A, Scatena F, Capria A. Treatment of patients with acute ulcerative colitis: conventional corticosteroid therapy versus granulocytapheresis. A pilot study. Dig. Liver Dis.39, 430–434 (2007).
   PubMedGoogle Scholar
• Ljung T, Thomsen OØ, Vatn M et al. Granulocyte, monocyte/macrophage apheresis for inflammatory bowel disease: the first 100 patients treated in Scandinavia. Scand. J. Gastroenterol.42(2), 221–227 (2007).
   PubMed Web of Science ®Google Scholar
• Panés J, Guilera M, Ginard D et al. Treatment cost of ulcerative colitis. Is apheresis with Adacolumn cost-effective? Dig. Liver Dis.39, 617–625 (2007).
   PubMedGoogle Scholar
• Cabriada JL, Doménech E, Gomollón F et al. Consensus document on the use of granulocytapheresis in patients with inflammatory bowel disease. Gastroenterol. Hepatol.29(2), 85–92 (2006).
   PubMedGoogle Scholar